Qualigen Therapeutics Statistics
Total Valuation
QLGN has a market cap or net worth of $2.73 million. The enterprise value is $3.54 million.
Important Dates
The next estimated earnings date is Friday, August 22, 2025, after market close.
| Earnings Date | Aug 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
QLGN has 1.64 million shares outstanding. The number of shares has increased by 554.32% in one year.
| Current Share Class | 1.64M |
| Shares Outstanding | 1.64M |
| Shares Change (YoY) | +554.32% |
| Shares Change (QoQ) | +85.41% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 2.70% |
| Float | 1.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 82.43 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 25.46.
| Current Ratio | 1.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | 25.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.69 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -211.25% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -19,640.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.73M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QLGN has paid $4,583 in taxes.
| Income Tax | 4,583 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.55% in the last 52 weeks. The beta is -0.17, so QLGN's price volatility has been lower than the market average.
| Beta (5Y) | -0.17 |
| 52-Week Price Change | -83.55% |
| 50-Day Moving Average | 3.11 |
| 200-Day Moving Average | 3.65 |
| Relative Strength Index (RSI) | 21.41 |
| Average Volume (20 Days) | 184,610 |
Short Selling Information
The latest short interest is 52,725, so 3.22% of the outstanding shares have been sold short.
| Short Interest | 52,725 |
| Short Previous Month | 25,038 |
| Short % of Shares Out | 3.22% |
| Short % of Float | 3.22% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | 306,537 |
| Operating Income | -6.51M |
| Pretax Income | -11.64M |
| Net Income | -6.90M |
| EBITDA | n/a |
| EBIT | -6.51M |
| Earnings Per Share (EPS) | -$9.91 |
Full Income StatementBalance Sheet
The company has $30,210 in cash and $843,615 in debt, giving a net cash position of -$813,405 or -$0.50 per share.
| Cash & Cash Equivalents | 30,210 |
| Total Debt | 843,615 |
| Net Cash | -813,405 |
| Net Cash Per Share | -$0.50 |
| Equity (Book Value) | 33,134 |
| Book Value Per Share | -1.72 |
| Working Capital | 31,134 |
Full Balance SheetCash Flow
| Operating Cash Flow | -7.13M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.13M |
| FCF Per Share | -$4.36 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |